BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
FABP1
,
Angiogenesis
,
HIV infection
,
Neuron
,
Nosology
,
Fenofibrate
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
su101
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Green, mildly synthesized bismuth-based MOF for extraction of polar glucocorticoids in environmental…
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) recep…
Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts…
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate …
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ